Progressive multifocal leukoencephalopathy therapy

Journal of NeuroVirology

Volumn 21, Issue 6, 2015, Pages 632-636

  Clifford, David B ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Immune reconstitution inflammatory syndrome; IRIS; JC virus; Natalizumab; PML; Progressive multifocal leukoencephalopathy

Indexed keywords

BETA INTERFERON; CIDOFOVIR; CORTICOSTEROID; CYTARABINE; INTERLEUKIN 2; MIRTAZAPINE; NATALIZUMAB; RECOMBINANT INTERLEUKIN 7;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; BRAIN DAMAGE; DEMYELINATION; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE DEFICIENCY; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOSURVEILLANCE; INFLAMMATION; JC VIRUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIA; OPPORTUNISTIC INFECTION; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; SURVIVAL; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; VIROLOGY;

HUMANS; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL;

EID: 84945970845     PISSN: 13550284     EISSN: 15382443     Source Type: Journal    
DOI: 10.1007/s13365-014-0289-8     Document Type: Article

References (31)

1. Antoniol C, Jilek S, Schluep M et al (2012) Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management? Neurology 79:2258–2264
2. Assetta B, Maginnis MS, Gracia Ahufinger I et al (2013) 5-HT2 receptors facilitate JC polyomavirus entry. J Virol 87:13490–13498
3. Berger JR, Levy RM, Flomenhoft D, Dobbs M (1998) Predictive factors for prolonged survival in acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy. Ann Neurol 44:341–349
4. Bloomgren G, Richman S, Hotermans C et al (2012) Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366:1870–1880
5. Brickelmaier M, Lugovskoy A, Kartikeyan R et al (2009) Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother 53:1840–1849
6. Cinque P, Pierotti C, Vigano MG et al (2001) The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy. J Neurovirol 7:358–363
7. Clifford DB, Team NARCS (1998) Impact on highly active antiretroviral therapy on survival from progressive multifocal leukoencephalopathy in human immunodeficiency virus infection. Neurology 50:A249
8. Clifford DB, DeLuca A, Simpson DM, Arendt G, Giovannoni G, Nath A (2010) Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 9:438–446
9. Clifford DB, Ances B, Costello C et al (2011) Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 68:1156–1164
10. Clifford DB, Nath A, Cinque P et al (2013) A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes. J Neurovirol 19:351–358
11. De Luca A, Ammassari A, Pezzotti P et al (2008) Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis. AIDS 22:1759–1767
12. Elphick GF, Querbes W, Jordan JA et al (2004) The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 306:1380–1383
13. Gadzia J, Turner J (2010) Progressive multifocal leukoencephalopathy in two psoriasis patients treated with efalizumab. J Drugs Dermatol 9:1005–1009
14. Gasnault J, Costagliola D, Hendel-Chavez H et al (2011) Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early 5-drug combination antiretroviral therapy. PLoS One 6:e20967
15. Geschwind MD, Skolasky RI, Royal WS, McArthur JC (2001) The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy in AIDS. JNeurovirol 7:353–357
16. Giacomini PS, Rozenberg A, Metz I et al (2014) Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome. N Engl J Med 370:486–488
17. Glass WG, Hickey MJ, Hardison JL, Liu MT, Manning JE, Lane TE (2004) Antibody targeting of the CC chemokine ligand 5 results in diminished leukocyte infiltration into the central nervous system and reduced neurologic disease in a viral model of multiple sclerosis. J Immunol 172:4018–4025
18. Gray F, Bazille C, Adle-Biassette H, Mikol J, Moulignier A, Scaravilli F (2005) Central nervous system immune reconstitution disease in acquired immunodeficiency syndrome patients receiving highly active antiretroviral treatment. J Neurovirol 11(Suppl 3):16–22
19. Hall CD, Dafni U, Simpson D et al (1998) Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. N Engl J Med 338:1345–1351
20. Hou J, Major EO (1998) The efficacy of nucleoside analogs against JC virus multiplication in a persistently infected human fetal brain cell line. J Neurovirol 4:451–456
21. Huang D, Cossoy M, Li M et al (2007) Inflammatory progressive multifocal leukoencephalopathy in human immunodeficiency virus-negative patients. Ann Neurol 62:34–39
22. Kappos L, Bates D, Edan G et al (2011) Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 10:745–758
23. Khatri B, Fox R, Koo A et al (2007) The effect of plasma exchange in accelerating clearance of natalizumab in patients with multiple sclerosis: results of the PLEX study (poster presented at 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis - ECTRIMS). Mult Scler 13:S172
24. Kunschner L, Scott TF (2005) Sustained recovery of progressive multifocal leukoencephalopathy after treatment with IL-2. Neurology 65:1510
25. Marra CM, Rajicic N, Barker DE et al (2002) A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. AIDS 16:1–7
26. Martin-Blondel G, Cuzin L, Delobel P et al (2009) Is maraviroc beneficial in paradoxical progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome management? AIDS 23:2545–2546
27. Patel A, Patel J, Ikwuagwu J (2010) A case of progressive multifocal leukoencephalopathy and idiopathic CD4+ lymphocytopenia. J Antimicrob Chemother 65:2697–2698
28. Reshef R, Luger SM, Hexner EO et al (2012) Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N Engl J Med 367:135–145
29. Tan K, Roda R, Ostrow L, McArthur J, Nath A (2009) PML-IRIS in patients with HIV infection. Clinical manifestations and treatment with steroids. Neurology 72:1458–1464
30. Tan IL, McArthur JC, Clifford DB, Major EO, Nath A (2011) Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology 77:1061–1067
31. Yousry TA, Major EO, Ryschkewitsch C et al (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354:924–933